Haifa, Israel: The administration of aerosolized cannabis via a novel inhaler is associated with long-term pain reductions in patients with neuropathy and other chronic conditions, according to data published in the journal Pain Reports.
Israeli investigators assessed the efficacy of cannabis delivered via a novel metered selective dose inhaler (The Syqe Inhaler) in a cohort of chronic pain patients. The mean daily stable dose used by patients in the study was 1.5 mg of aerosolized delta-9-THC.
Use of the inhaler over a period of several months was associated with reduced pain scores and improvements in patients’ quality of life. Some patients reported mild side-effects (typically dizziness and sleepiness) at the onset of the study, but few participants continued to report these effects throughout the duration of the trial.
Authors concluded: “Medical cannabis treatment with the Syqe Inhaler demonstrated overall long-term pain reduction[s], quality of life improvement[s], and opioid-sparing effect[s] in a cohort of patients with chronic pain, using just a fraction of the amount of MC [medical cannabis] compared with other modes of delivery by inhalation. These outcomes were accompanied by a lower rate of AEs [adverse events] and almost no AE reports during a long-term steady-state follow-up. Additional follow-up in a larger population is warranted to corroborate our findings.”
According to recently compiled survey data, nearly one in three chronic pain patients report using cannabis for treatment management. Among patients in US states where medical cannabis access is permitted, over 60 percent are qualified to use it to treat pain.
Full text of the study, “Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe Inhaler,” appears in Pain Reports. Additional information on cannabis and chronic pain is available from NORML.